glycine has been researched along with Pulmonary Disease, Chronic Obstructive in 8 studies
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD." | 9.20 | A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease. ( Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X, 2015) |
| " The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD." | 5.20 | A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease. ( Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X, 2015) |
| "We investigated changes to the leukotriene A4 hydrolase (LTA4H)-proline-glycine-proline (PGP) pathway and chronic inflammation in the development of COPD." | 5.19 | An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. ( Blalock, JE; Gaggar, A; Garrett, C; Handley, G; Jackson, PL; McNicholas, CM; Miller, BE; O'Reilly, PJ; Rennard, SI; Roda, MA; Sullivan, DI; Szul, T; Tal-Singer, R; Wells, JM, 2014) |
| "Severe COPD exacerbations were recorded at 1-year of prospective follow-up." | 2.90 | The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS. ( Barjaktarevic, I; Bhatt, SP; Blalock, JE; Burkes, RM; Couper, DJ; Curtis, JL; Dransfield, MT; Freeman, CM; Gaggar, A; Han, MLK; Hoffman, EA; Labaki, WW; O'Neal, W; Putcha, N; Schlange, T; Viera, L; Wells, JM; Wu, Y; Xing, D, 2019) |
| "Chronic obstructive pulmonary disease (COPD) is a major increasing health problem and the World Health Organization (WHO) reports COPD as the fifth leading cause of death worldwide." | 2.49 | Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. ( Costa, E; Guedes, RC; Lucas, SD; Moreira, R, 2013) |
| "Each glycine (Gly) copy was associated with a higher number of exacerbations (OR: 0." | 1.72 | Clinical course of COPD in patients with Arg16Gly (rs1042713) polymorphism of ADRB2 gene. ( Dmytriiev, K; Mostovoy, Y; Slepchenko, N; Smereka, Y, 2022) |
| "In patients with acute exacerbations of COPD (AECOPD), we assessed the role of ADRB2 haplotypes in morning lung function and in the bronchodilator response to salbutamol." | 1.35 | Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. ( Habalova, V; Joppa, P; Kluchova, Z; Micietova, L; Mokry, M; Rozborilova, E; Salagovic, J; Slaba, E; Tkacova, R; Zidzik, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Potyazhenko, MM | 1 |
| Nastroga, TV | 1 |
| Sokolyuk, NL | 1 |
| Kitura, OY | 1 |
| Motorna, NM | 1 |
| Korpan, AS | 1 |
| Dmytriiev, K | 1 |
| Mostovoy, Y | 1 |
| Slepchenko, N | 1 |
| Smereka, Y | 1 |
| Wells, JM | 3 |
| Xing, D | 1 |
| Viera, L | 2 |
| Burkes, RM | 1 |
| Wu, Y | 1 |
| Bhatt, SP | 2 |
| Dransfield, MT | 2 |
| Couper, DJ | 1 |
| O'Neal, W | 1 |
| Hoffman, EA | 1 |
| Gaggar, A | 3 |
| Barjaktarevic, I | 1 |
| Curtis, JL | 1 |
| Labaki, WW | 1 |
| Han, MLK | 1 |
| Freeman, CM | 1 |
| Putcha, N | 1 |
| Schlange, T | 1 |
| Blalock, JE | 3 |
| O'Reilly, PJ | 1 |
| Szul, T | 1 |
| Sullivan, DI | 1 |
| Handley, G | 2 |
| Garrett, C | 1 |
| McNicholas, CM | 1 |
| Roda, MA | 1 |
| Miller, BE | 1 |
| Tal-Singer, R | 1 |
| Rennard, SI | 1 |
| Jackson, PL | 2 |
| Gautney, J | 1 |
| King, RW | 1 |
| Xu, X | 1 |
| Bailey, WC | 1 |
| Li, MX | 1 |
| Chen, YH | 1 |
| Liao, CC | 1 |
| Lin, F | 1 |
| Bai, Y | 1 |
| Mi, WJ | 1 |
| Sun, Y | 1 |
| Qi, YF | 1 |
| Mokry, M | 1 |
| Joppa, P | 1 |
| Slaba, E | 1 |
| Zidzik, J | 1 |
| Habalova, V | 1 |
| Kluchova, Z | 1 |
| Micietova, L | 1 |
| Rozborilova, E | 1 |
| Salagovic, J | 1 |
| Tkacova, R | 1 |
| Lucas, SD | 1 |
| Costa, E | 1 |
| Guedes, RC | 1 |
| Moreira, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Subpopulations and Intermediate Outcome Measures in COPD Study[NCT01969344] | 2,981 participants (Actual) | Observational | 2010-11-30 | Active, not recruiting | |||
| A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time[NCT00292552] | 2,747 participants (Actual) | Observational | 2005-12-31 | Completed | |||
| A Placebo-controlled Trial of Roflumilast (Daliresp) on Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD)[NCT01572948] | 27 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01572948)
Timeframe: 1 month
| Intervention | percentage of sputum neutrophils (Mean) |
|---|---|
| Placebo | 83 |
| Daliresp | 80 |
(NCT01572948)
Timeframe: 3 months after baseline
| Intervention | percentage of sputum neutrophils (Mean) |
|---|---|
| Placebo | 86 |
| Roflumilast | 58 |
(NCT01572948)
Timeframe: baseline
| Intervention | percentage of sputum neutrophils (Mean) |
|---|---|
| Placebo | 89 |
| Roflumilast | 83 |
(NCT01572948)
Timeframe: baseline
| Intervention | ng/ml (Mean) |
|---|---|
| Placebo | 0.74 |
| Roflumilast | 0.64 |
(NCT01572948)
Timeframe: 1 month after baseline
| Intervention | ng/ml (Mean) |
|---|---|
| Roflumilast | .33 |
| Placebo | .66 |
(NCT01572948)
Timeframe: 3 months after baseline
| Intervention | ng/ml (Mean) |
|---|---|
| Placebo | 0.70 |
| Roflumilast | 0.30 |
1 review available for glycine and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase.
Topics: Enzyme Inhibitors; Glycine; Humans; Molecular Weight; Proteinase Inhibitory Proteins, Secretory; Pul | 2013 |
3 trials available for glycine and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS.
Topics: Aged; Biomarkers; Cohort Studies; Female; Glycine; Humans; Male; Middle Aged; Proline; Prospective S | 2019 |
An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease.
Topics: Aged; Animals; Bronchoalveolar Lavage Fluid; Cohort Studies; Disease Models, Animal; Emphysema; Epox | 2014 |
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aminopyridines; Benzamides; Bronchitis, Chronic; Cyclopropanes; Double-Blind Method; Epoxide H | 2015 |
4 other studies available for glycine and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
EFFICIENT COMPREHENSIVE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION AND POSTCOVIDAL SYNDROME IN ELDERLY PATIENTS.
Topics: Acetylcysteine; Aged; COVID-19; COVID-19 Drug Treatment; Glycine; Humans; Middle Aged; Pulmonary Dis | 2022 |
Clinical course of COPD in patients with Arg16Gly (rs1042713) polymorphism of ADRB2 gene.
Topics: Arginine; Bronchodilator Agents; Disease Progression; Glycine; Humans; Polymorphism, Genetic; Pulmon | 2022 |
[Role and mechanism of hydrogen sulfide in cigarette smoke induced chronic obstructive pulmonary disease related pulmonary vascular remodeling in rats].
Topics: Alkynes; Animals; Glycine; Hydrogen Sulfide; Lung; Male; Nicotiana; Pulmonary Artery; Pulmonary Dise | 2017 |
Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD.
Topics: Adult; Aged; Albuterol; Bronchodilator Agents; Codon; Demography; Female; Glutamic Acid; Glycine; Ha | 2008 |